Cellumed Completes Process Improvements for Skin Product, Significantly Enhances Usability in Clinical Settings

Cellumed, a subsidiary of InskoBi Group specializing in the manufacture of bio-medical devices, announced on August 19 that it has completed process improvements and product upgrades for its skin graft material, 'CELLUDERM HD IMPLANT,' by incorporating feedback from professional medical staff who are actual users in the clinical field.

This round of improvements focused on enhancing the precision of the cutting process and the finishing quality of the 'CELLUDERM HD IMPLANT,' which is primarily used in breast reconstruction surgery. In particular, based on feedback from plastic and breast surgeons who use the product in actual procedures, the company improved operability and intuitive usability, and also optimized the structural design and surface treatment to minimize the foreign body sensation experienced by patients. Through these enhancements, Cellumed expects to achieve clinical benefits such as reduced surgery time and a lower incidence of complications.

Cellumed has been advancing technology centered on clinical needs through collaboration with medical professionals in various specialties, including plastic surgery, breast surgery, orthopedics, and urology. With this product upgrade, the range of applications and user convenience of the 'CELLUDERM HD IMPLANT' have been significantly improved, and the company anticipates that expanded domestic and international supply in the second half of the year will have a positive impact on sales growth.

Currently, Cellumed offers the 'CELLUDERM' series, including CELLUDERM POWER and CELLUDERM ULTRA, which are specialized for various indications. Recently, the company also completed the development of injectable products, CELLUDERM FILL and CELLUDERM GEN, further strengthening its portfolio. The 'CELLUDERM' series is an acellular allogeneic dermal tissue graft that has earned high trust in the medical field due to its excellent biocompatibility and low infection rate.

A Cellumed representative stated, "We plan to continue investing in technological advancement and quality improvement by reflecting the real needs of the clinical field," adding, "We will enhance product competitiveness based on the trust of medical professionals and actively pursue sales expansion in the second half of the year."